Methotrexate Pellet Formulation for Saturation Kinetics
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Methotrexate oral formulations face limitations due to saturation kinetics, leading to reduced bioavailability and increased side effects at higher doses, and existing technologies struggle to provide flexible dosage forms and release profiles suitable for individual patient needs.
Innovation Solution
Development of pharmaceutical compositions comprising pellets with varying release profiles, including immediate and delayed release formulations, allowing for customizable dosages and release times to enhance bioavailability and minimize side effects, while simplifying manufacturing processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If the amount of methotrexate in a single dosage form is increased to improve clinical effect, then the dosage strength is improved, but saturation of active transport mechanisms occurs leading to reduced bioavailability and increased side effects
Solution Approach 1:
The patent divides a high-dose methotrexate formulation into multiple pellets, each containing a low dose (e.g., 2.5 mg). This segmentation allows the total therapeutic dose to be delivered while each individual pellet releases methotrexate below the saturation threshold of active transport mechanisms, thereby maintaining high bioavailability and reducing side effects.
2Quantity of substance
If the amount of methotrexate in a single dosage form is increased to improve clinical effect, then the dosage strength is improved, but side effects increase due to uptake in non-target cells
Solution Approach 1:
By segmenting the total dose into multiple low-dose pellets, the patent ensures that methotrexate is released in amounts that do not saturate transport mechanisms or cause excessive uptake in non-target cells, thereby delivering the required dosage strength while minimizing harmful side effects.
Solution Approach 2:
The patent applies different release characteristics to different pellets within the same dosage form. Some pellets are designed for immediate release while others provide delayed release, creating local variations in release profiles that optimize therapeutic effect and minimize toxicity in different gastrointestinal regions.
3Adaptability or versatility
If multiple different pharmaceutical formulations with different strengths and release characteristics are produced to meet individual patient needs, then adaptability is improved, but manufacturing complexity and cost increase
Solution Approach 1:
The patent merges multiple dosage strengths and release characteristics into a single pellet formulation. By adjusting the number of pellets administered, different total doses can be achieved, and by using pellets with different release profiles (immediate and delayed), various release characteristics can be obtained, all from the same base formulation.
Solution Approach 2:
The patent creates a universal pellet formulation that can serve multiple dosing requirements. The same pellet type can be used to achieve different total doses by varying the number of pellets, and different release profiles can be obtained by combining pellets with different characteristics, making the formulation adaptable to various patient needs without requiring separate manufacturing lines.
Data Source
AI summary
The present invention relates to a pharmaceutical dosage form comprising an active ingredient such as methotrexate or a pharmaceutically acceptable salt thereof, in particular in the form of pellets, such as multiparticulates, mini-tablets or granulate. It further relates to oral dosage forms for which saturation kinetics limits the oral use of higher dosages of active ingredients.